Q1 FY2027 EarningsQ1 FY27 revenue missed consensus slightly at $1.77M vs. $1.93M expected, while gross margin of 12.7% fell significantly short of the 22.0% estimate. Despite the top-line and margin pressure, operating loss was narrower than expected due to disciplined R&D spending. Management reaffirmed CY2026 and CY2027 revenue guidance, signaling a potential inflection point pending the H2 CY2026 approval of the second-generation LungFit PH system.